84 related articles for article (PubMed ID: 9917497)
21. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma.
Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR
Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687
[TBL] [Abstract][Full Text] [Related]
22. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
23. Adoptive immunotherapy of HCMV infection.
Kapp M; Tan SM; Einsele H; Grigoleit G
Cytotherapy; 2007; 9(8):699-711. PubMed ID: 17917875
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.
Sandri S; Bobisse S; Moxley K; Lamolinara A; De Sanctis F; Boschi F; Sbarbati A; Fracasso G; Ferrarini G; Hendriks RW; Cavallini C; Scupoli MT; Sartoris S; Iezzi M; Nishimura MI; Bronte V; Ugel S
Cancer Res; 2016 May; 76(9):2540-51. PubMed ID: 27197263
[TBL] [Abstract][Full Text] [Related]
25. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.
Bai XF; Liu J; Li O; Zheng P; Liu Y
J Clin Invest; 2003 May; 111(10):1487-96. PubMed ID: 12750398
[TBL] [Abstract][Full Text] [Related]
26. Maturation and function of mouse T-cells with a transgenic TCR positively selected by highly disparate xenogeneic porcine MHC.
Zhao Y; Rodriguez-Barbosa JI; Zhao G; Shaffer J; Arn JS; Sykes M
Cell Mol Biol (Noisy-le-grand); 2001 Feb; 47(1):217-28. PubMed ID: 11292257
[TBL] [Abstract][Full Text] [Related]
27. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
28. Studies on the induction and expression of T cell-mediated immunity. XV. Role of non-MHC papain-sensitive target structures and Lyt-2 antigens in allogeneic and xenogeneic lectin-dependent cellular cytotoxicity (LDCC).
Bonavida B; Katz J
J Immunol; 1985 Sep; 135(3):1616-23. PubMed ID: 3874903
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
Cesano A; Visonneau S; Rovera G; Santoli D
Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
[TBL] [Abstract][Full Text] [Related]
31. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
Matsui K; O'Mara LA; Allen PM
Int Immunol; 2003 Jul; 15(7):797-805. PubMed ID: 12807818
[TBL] [Abstract][Full Text] [Related]
32. Differentiation between MHC-restricted and non-MHC-restricted porcine cytolytic T lymphocytes.
Pauly T; Weiland E; Hirt W; Dreyer-Bux C; Maurer S; Summerfield A; Saalmüller A
Immunology; 1996 Jun; 88(2):238-46. PubMed ID: 8690456
[TBL] [Abstract][Full Text] [Related]
33. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
[TBL] [Abstract][Full Text] [Related]
34. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
35. Limiting dilution analysis of the allo-MHC anti-paternal cytotoxic T cell response. II: Recurrent spontaneous abortion and the effect of immunotherapy.
Manyonda IT; Pereira RS; Pearce JM; Sharrock CE
Clin Exp Immunol; 1993 Jul; 93(1):132-7. PubMed ID: 8324899
[TBL] [Abstract][Full Text] [Related]
36. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
37. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
38. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
39. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor.
Mahon BP; Katrak K; Nomoto A; Macadam AJ; Minor PD; Mills KH
J Exp Med; 1995 Apr; 181(4):1285-92. PubMed ID: 7699320
[TBL] [Abstract][Full Text] [Related]
40. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
